Biosimilars: A Fancy Name for Generics But Oh So Much More Disastrous | GenomeWeb

Over on VentureBeat, David Hamilton writes that even normally smart biotechnology investors get a little dim when talking about biosimilars and the loss of patent protection for biotech drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.